Review
BibTex RIS Cite

Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me

Year 2018, , 109 - 112, 05.03.2018
https://doi.org/10.16948/zktipb.322632

Abstract




Medication use
in pregnancy is a common problem and question. Nearly half of pregnant women (30%
-90%) use at least one prescription medication during pregnancy. In addition to
prescription drugs, pregnant women use over the counter drugs for which are
limited data in pregnancy. Pregnant patients exposed to drugs should be
informed about potential effects of medications. The United States- Food and
Drug Administration’s (US- FDA) pregnancy categories (A, B, C, D, and X), which
provide short and practical data, have recently been removed and replaced with
an evidence-based approach.
An
overall classification for pregnancy is not sufficient when used alone. A
research-based risk evaluation of potential adverse
health effects resulting from drug use in pregnancy has three important parts:
risk assessment, risk communication and risk management.
An accurate
risk
evaluation about drug
safety in pregnancy and informing women exposed to drugs may help
reduce maternal concerns and prevent unnecessary
pregnancy terminations.




References

  • Daw JR, Hanley GE, Greyson DL, Morgan SG. 1. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011;20(9):895-902.
  • Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1-8.
  • Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME, Drozd M, Panchaud A, Hämeen-Anttila K, Rieutord A, Gjergja Juraski R, Odalovic M, Kennedy D, Rudolf G, Juch H, Passier A, Björnsdóttir I, Nordeng H. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365.
  • Glover DD, Rybeck BF, Tracy TS. Medication use in a rural gynecologic population: prescription, over-the-counter, and herbal medicines. Am J Obstet Gynecol. 2004;190(2):351-7.
  • İskit AB. Gebe hastada ilaç seçimi. Sürekli Tıp Eğitimi Dergisi. 2007;16 (1): 15-7.
  • Öztürk Z. İlaç Kullanan Gebeye Yaklaşım. Sürekli Tıp Eğitimi Dergisi. 2014;23 (5): 201-5.
  • Honein MA, Gilboa SM, Broussard CS. The Need for Safer Medication Use in Pregnancy. Expert Rev Clin Pharmacol. 2013;6(5):453-5.
  • Schaefer C1, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. Reprod Toxicol. 2008;26(1):36-41.
  • Sinclair SM, Miller RK, Chambers C, Cooper EM. Medication Safety During Pregnancy: Improving Evidence-Based Practice. J Midwifery Womens Health 2016;61:52-67.
  • Pines A. Patient information leaflets: friend or foe? Climacteric 2015;18:663-5.

Gebelikte İlaç Kullanımı ve Risk Değerlendirmesi: Beni Kategorize Etme

Year 2018, , 109 - 112, 05.03.2018
https://doi.org/10.16948/zktipb.322632

Abstract




Gebelikte ilaç kullanımı sık karşılaşılan bir sorun
ve sorudur. Gebe kadınların yaklaşık yarısı (%30-90) gebeliğinde en azından bir
tane reçetelenmiş ilaç kullanmaktadır. Reçetelenmiş ilaçalara ek olarak gebe
kadınlar, gebelikte kullanımları hakkında sınırlı veri bulunan tezgah üstü
ilaçları da kullanmaktadırlar. İlaca maruz kalmış gebe hastalar, ilaçların olası
etkileri hakkında bilgilendirilmelidir. Amerikan Gıda ve İlaç Dairesi (US-FDA)
gebelik kategorileri (A, B, C, D, ve X), konuyla ilgili kısa ve pratik bilgi
sağlamakla birlikte yakın zamanda kaldırılmış olup yerine kanıta dayalı bir
yaklaşım benimsenmiştir. Gebelik için bu şekilde genel bir sınıflama tek başına
kullanıldığında yeterli olmamaktadır. Gebelikte ilaç kullanımı sonucu
oluşabilecek istenmeyen etkilere dair araştırma- tabanlı bir risk
değerlendirmesi, üç önemli bölümden oluşmaktadır: risk ölçümü, risk iletişimi
ve risk yönetimi.Gebelikte ilaç güvenliği hakkında eksiksiz bir risk
değerlendirmesi ve ilaca maruz kalmış kadınların bilgilendirilmesi hem gebedeki
endişeyi azaltabilir, hem de gereksiz gebelik sonlandırmalarının önüne
geçebilir.




References

  • Daw JR, Hanley GE, Greyson DL, Morgan SG. 1. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011;20(9):895-902.
  • Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1-8.
  • Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME, Drozd M, Panchaud A, Hämeen-Anttila K, Rieutord A, Gjergja Juraski R, Odalovic M, Kennedy D, Rudolf G, Juch H, Passier A, Björnsdóttir I, Nordeng H. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365.
  • Glover DD, Rybeck BF, Tracy TS. Medication use in a rural gynecologic population: prescription, over-the-counter, and herbal medicines. Am J Obstet Gynecol. 2004;190(2):351-7.
  • İskit AB. Gebe hastada ilaç seçimi. Sürekli Tıp Eğitimi Dergisi. 2007;16 (1): 15-7.
  • Öztürk Z. İlaç Kullanan Gebeye Yaklaşım. Sürekli Tıp Eğitimi Dergisi. 2014;23 (5): 201-5.
  • Honein MA, Gilboa SM, Broussard CS. The Need for Safer Medication Use in Pregnancy. Expert Rev Clin Pharmacol. 2013;6(5):453-5.
  • Schaefer C1, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. Reprod Toxicol. 2008;26(1):36-41.
  • Sinclair SM, Miller RK, Chambers C, Cooper EM. Medication Safety During Pregnancy: Improving Evidence-Based Practice. J Midwifery Womens Health 2016;61:52-67.
  • Pines A. Patient information leaflets: friend or foe? Climacteric 2015;18:663-5.
There are 10 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Review
Authors

Zeynep Öztürk

Publication Date March 5, 2018
Published in Issue Year 2018

Cite

APA Öztürk, Z. (2018). Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me. Zeynep Kamil Tıp Bülteni, 49(1), 109-112. https://doi.org/10.16948/zktipb.322632
AMA Öztürk Z. Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me. Zeynep Kamil Tıp Bülteni. March 2018;49(1):109-112. doi:10.16948/zktipb.322632
Chicago Öztürk, Zeynep. “Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me”. Zeynep Kamil Tıp Bülteni 49, no. 1 (March 2018): 109-12. https://doi.org/10.16948/zktipb.322632.
EndNote Öztürk Z (March 1, 2018) Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me. Zeynep Kamil Tıp Bülteni 49 1 109–112.
IEEE Z. Öztürk, “Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me”, Zeynep Kamil Tıp Bülteni, vol. 49, no. 1, pp. 109–112, 2018, doi: 10.16948/zktipb.322632.
ISNAD Öztürk, Zeynep. “Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me”. Zeynep Kamil Tıp Bülteni 49/1 (March 2018), 109-112. https://doi.org/10.16948/zktipb.322632.
JAMA Öztürk Z. Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me. Zeynep Kamil Tıp Bülteni. 2018;49:109–112.
MLA Öztürk, Zeynep. “Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me”. Zeynep Kamil Tıp Bülteni, vol. 49, no. 1, 2018, pp. 109-12, doi:10.16948/zktipb.322632.
Vancouver Öztürk Z. Medication Use in Pregnancy and Risk Evaluation: Do Not Categorize Me. Zeynep Kamil Tıp Bülteni. 2018;49(1):109-12.